Revenue Cycle Insider

Path/Lab Coding:

Let These 5 Takeaways Inform Your MoPath Coding

Here’s how to narrow down complex lab reports to a specific code.

“Molecular pathology [MoPath] is one of the fastest-growing areas in medicine and coding right now,” according to Lawrence Simon, MD, MBA, member of the CPT® Editorial Panel and co-chair of the Molecular Pathology Advisory Group. To help keep track of these rapid developments, Simon explained how CPT® constructs the MoPath codes and how to use that information when interpreting lab reports for correct code assignment in his talk, “Path/Lab Coding Update for 2026: Genes, Nuances, and Other Critical Updates,” at this year’s HEALTHCON Regional.

Here are five takeaways from that talk that might help anyone coding in the path/lab field.

Takeaway 1: Understand What MoPath Is

Simon began by offering a definition of MoPath, which is “the application of diagnostic molecular pathology and genomics in the evaluation and management of human disease,” according to Ron McLawhon, chair of the CPT® Pathology Coding Caucus. Essentially, this means using a person’s DNA, or a copy of that DNA known as RNA, to:

  • Test for molecular diseases through detection of microorganisms;
  • Test for heritable mutations or constitutional disorders using germline or genetic testing; and
  • Test for neoplasia/cancer and other acquired mutations through somatic testing.

In particular, MoPath testing looks for biomarkers (also called molecular markers, or signature molecules) that are signs of conditions, diseases, or abnormal or normal processes in the body. Not only can these biomarkers help detect the condition, but they can also help predict how well the body will respond to treatment for that condition.

Lab, scientist, samples, microscope, computer

Takeaway 2: Understand the Difference Between Tier 1 and Tier 2 Codes

Simon went on to note that MoPath tests begin by employing a technique known as polymerase chain reaction (PCR), which enables copying of a large amount of the patient’s DNA from the initial sample. From there, the tests can employ Sanger sequencing, which is a long, resource-intensive sequencing of a single gene.

MoPath test codes are grouped together as tier 1 codes, which test one specific gene or gene variant and are found in the 81105-81364 section of the CPT® code book, with human leukocyte antigen (HLA) typing procedures (tests that use DNA sequencing to map HLA genes in order to find transplant donor matches or assess risks for certain diseases) appearing in the 81170-81383 (Tier 1 Molecular Pathology Procedures) range.

Tier 2 MoPath test codes in the 81400-81408 (Tier 2 Molecular Pathology Procedures) range differ in that they examine multiple genes and are less frequently performed, as the conditions they are testing for are generally rare. Tier 2 codes also reflect a much greater amount of work on behalf of the lab performing them.

Takeaway 3: Understand GSPs

Rather than looking for individual genes, genomic sequencing procedures (GSPs) and other molecular multianalyte assay tests are looking for various mutations in a patient’s DNA sequencing. The tests utilize next generation sequencing (NGS) or massively parallel sequencing (MPS) to quickly process the huge amount of information contained in the patient’s DNA or RNA sample.

After the sequencing, the DNA or RNA is spliced to remove certain features that do not provide critical information before examining more significant features, such as variants of a single nucleotide, a deletion or insertion of a whole sequence, whether a segment of DNA has been incorrectly copied from a parent (known as a copy number variant), or whether the structure of the DNA segment has varied from the original. The tests can also predict how well a patient will respond to immunotherapy for cancer by looking for tumor mutation burden (TMB) biomarkers and microsatellite instability (MSI). These all appear in the CPT® code book in the 81409-81479 (Genomic sequencing procedures and other molecular multianalyte assays) range.

Top tip: For labs that work with or for cancer centers or oncology practices, Simon recommended using the CPT® lookup chart to precisely locate codes for GSPs used to profile solid organ or blood cancers (codes 81445-81464) in the GSP section. The chart breaks down the tests by cancer type as well as by methodology.

Takeaway 4: Understand MAAAs

Like GSPs, multianalyte assays with algorithmic analyses (MAAAs) are panels, with one important difference: the tests add additional data, such as a patient history or age, which is then combined with the panel and run through a proprietary algorithm, according to Simon. These tests can be found in the 81490-81599 (Multianalyte assays with algorithmic analyses) range of the CPT® code book.

Takeaway 5: Use These Takeaways (and More) to Identify the Correct Code

Simon concluded his talk with the following suggestions to enable you to sift through even the largest lab report and locate the correct code to describe the test performed:

  • Familiarize yourself with the definitions provided in the various MoPath introductory sections of the CPT® code book.
  • In the lab report itself, look for individual gene names and testing methodologies (such as PCR, NGS, GSPs, MAAAs, germline testing, or somatic testing).
  • Make use of the Molecular Pathology Gene Table located at the beginning of the Pathology and Laboratory section of the CPT® code book. The table lists all the single genes that have an associated test, according to Simon.
  • If the lab report includes a test with a score, the test is using a proprietary algorithm. To find the correct co for these tests, refer to Appendix O, the MAAA and proprietary lab analysis (PLA) appendix of the CPT® code book.
  • Make use of CPT® Assistant and CPT® Changes. CPT® Changes in particular is helpful as it gives the rationale behind code changes and a full description of the procedure and the work it entails.

Bruce Pegg, BA, MA, CPC, CFPC, Managing Editor, AAPC

Other Articles of

November 2026

View All
Subscribe to newsletter